3 ms·

I believe az had similar (bad) results which caused south africa to pause the rollout.

• petre 6y ago
  Yup, except none of the recipients in the AZ study had severe cases.
  • Barrin92 6y ago
    the problem is of course that even if that's true, if the virus spreads asymptomatically the same mutation risk applies to the variant itself and at some point then we might up with something that again completely escapes immunity and vaccination. It's just evolution in action. Any variant that dodges the vaccine starts a new game of dice.
    • petre 6y ago
      Well, what's the alternative? Get covid19 and risk death or life long ill effects? The virus mutates anyway in healty individuals that develop mild cases. There's enough of a scadal with the AZ vaccine in the EU, people don't want to get vaccinated with it because of blood clots with in DIC 0.35/1M and CVST in 0.9/1M individuals[1] and fever for a day, the company has rebdand it as Vaxzevria in an attempt to reduce the fallout. The vaccination rollout is not going well in the EU, it was even criticised by the WHO as being too slow. Yet this vaccine works and can probably stop the pandemic and save lives along with the others. I took my chanches and got vaccinated with it a week and a half ago, instead of waiting for something better and risk getting covid in the meantime. I might have taken Sputnik V as well if nothing else was available. AZ at least seems to work, was proven at least on 1/4 of the UK population. Their cases seem to go down. I guess we'll see. 1. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazene...
  • amluto 6y ago
    IIRC no one in either arm of that study had a serious case. The study was nearly useless.